Francois Roman

Summary

Affiliation: GlaxoSmithKline Biologicals
Country: Belgium

Publications

  1. doi Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial
    Francois Roman
    GlaxoSmithKline Biologicals, Avenue Fleming 20, 1300 Wavre, Belgium
    Vaccine 28:1740-5. 2010
  2. doi An assessment of prime-boost vaccination schedules with AS03A -adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults
    Paul Gillard
    GlaxoSmithKline Biologicals, Wavre, Belgium
    Influenza Other Respir Viruses 7:55-65. 2013
  3. pmc Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials
    Francois Roman
    GlaxoSmithKline Biologicals, Wavre, Belgium
    Clin Vaccine Immunol 18:835-43. 2011

Collaborators

Detail Information

Publications3

  1. doi Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial
    Francois Roman
    GlaxoSmithKline Biologicals, Avenue Fleming 20, 1300 Wavre, Belgium
    Vaccine 28:1740-5. 2010
    ....
  2. doi An assessment of prime-boost vaccination schedules with AS03A -adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults
    Paul Gillard
    GlaxoSmithKline Biologicals, Wavre, Belgium
    Influenza Other Respir Viruses 7:55-65. 2013
    ....
  3. pmc Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials
    Francois Roman
    GlaxoSmithKline Biologicals, Wavre, Belgium
    Clin Vaccine Immunol 18:835-43. 2011
    ..Baseline A/H1N1/2009-specific CD4⁺ T-cell frequencies did not predict post-dose 1 antibody responses, but there was some correlation between post-dose 1 CD4⁺ T-cell frequencies and post-dose 2 antibody responses...